What Is 2022-2023 mpox outbreak in Africa

Overview

The 2022-2023 mpox outbreak in Africa marked a significant resurgence of the disease, primarily affecting the Democratic Republic of the Congo (DRC) and spreading to neighboring countries. Unlike the global 2022 outbreak caused by clade II, this African outbreak involved the more virulent clade I virus, which has historically led to higher fatality rates and increased transmission in endemic regions.

Public health officials noted a sharp rise in cases beginning in early 2022, with sustained community transmission through 2023. The outbreak highlighted weaknesses in regional surveillance, vaccine access, and healthcare infrastructure. Below are key details about the scope, transmission, and response to the outbreak.

• Over 12,500 suspected cases were reported in the DRC alone between January 2022 and December 2023, with a case fatality rate of approximately 4.6%.
• Clade I of the mpox virus was responsible for this outbreak, which is more lethal than the clade II strain that spread globally in 2022.
• Human-to-human transmission occurred primarily through close contact with lesions, bodily fluids, or contaminated materials, especially in households and healthcare settings.
• Children under 15 accounted for over 95% of cases, a shift from previous patterns where adults were more commonly affected.
• Eight countries in Central and West Africa reported cases, including the DRC, Nigeria, Cameroon, and the Central African Republic.

How It Works

Understanding the 2022-2023 mpox outbreak in Africa requires knowledge of virology, transmission dynamics, and public health responses. The following terms explain key mechanisms and responses central to the outbreak.

• Clade I virus: This strain of mpox is endemic to Central Africa and has a case fatality rate of up to 10%, significantly higher than clade II’s 1–3%.
• Zoonotic spillover: The virus jumps from animals—mainly rodents—to humans, often through hunting or consuming bushmeat in forested regions.
• Incubation period: Symptoms typically appear 5–21 days after exposure, with fever, rash, and lymphadenopathy being common early signs.
• Vaccination access: The DRC had limited access to mpox vaccines, with only experimental doses deployed in select areas by late 2023.
• Genomic sequencing: Scientists used sequencing to confirm the outbreak was caused by a new sublineage of clade I, showing increased human adaptation.
• Public health emergency: The WHO declared the outbreak a PHEIC in August 2023, triggering international funding and coordination efforts.

Comparison at a Glance

The following table compares the 2022-2023 African mpox outbreak with the global 2022 outbreak.

While both outbreaks involved the mpox virus, the African 2022-2023 outbreak was more severe in terms of mortality and affected a different demographic. The global outbreak was less deadly but spread rapidly through international travel and sexual contact networks, whereas the African outbreak remained concentrated but more lethal due to limited healthcare access.

Why It Matters

The 2022-2023 mpox outbreak in Africa underscores the persistent threat of endemic zoonotic diseases and the need for sustained investment in public health infrastructure. The disproportionate impact on children and rural communities highlights systemic inequities in vaccine distribution and disease surveillance.

• High fatality rates in children under 15 emphasize the need for pediatric-focused treatment and prevention strategies.
• Limited vaccine supply in Africa delayed containment efforts, exposing gaps in global health equity.
• Increased human adaptation of the clade I virus raises concerns about potential for wider spread if not controlled.
• Stigma and misinformation hindered early reporting and contact tracing in affected communities.
• Need for regional surveillance systems to detect and respond to emerging pathogens before they escalate.
• International funding remained insufficient despite the WHO’s PHEIC declaration, slowing response timelines.

This outbreak serves as a critical reminder that neglected diseases in low-resource settings can evolve into larger threats without timely intervention and global cooperation.